Option chain shows key data for Can Fite Biofarma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Can Fite Biofarma.

Can Fite Biofarma (AMEX:CANF) Stock, Option Chain

Can Fite Biofarma

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

movers image

News

Intraday Update

Markets

Movers

Trading Ideas

ADBE

BAND

BIMI

CABA

CANF

CNSP

CORT

FOXO

GANX

INAB

IONM

IRON

JFBR

KAVL

KITT

KYTX

LGVN

NAAS

NNVC

NVAX

OCUL

ONMD

PENN

POWW

RARE

RNXT

RZLT

SVMH

THMO

TWOU

WLFC

Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Biotech

Equities

Penny Stocks

Health Care

General

Can-Fite BioPharma Ltd (NYSE: CANF) announced that a patient who participated in the Phase 2 Liver Cancer Study and was treated with namodenoson had a complete response and overall survival of 

Why Is Liver Cancer Focused Can-Fite BioPharma Stock Trading Higher Today?

Price Target

Small Cap

Analyst Ratings

ARVN

GOGL

MATX

MEDP

NRDS

SWAV

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page

Matson To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd

Canfor Corp

CANFOR PULP PRODUCTS INC by Canfor Pulp Products, Inc.

Canfor Pulp Products Inc

Press Releases

Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol

Earnings

Can-Fite Reports 2024 Financial Results and Clinical Update

Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Comments

Can Fite Biofarma

Can Fite Biofarma (CANF) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell